Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.868
Filtrar
1.
Mol Nutr Food Res ; 68(10): e2300657, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38698718

RESUMEN

SCOPE: Tocomonoenols (T1) are little-known vitamin E derivatives naturally occurring in foods. Limited knowledge exists regarding the cellular uptake and metabolism of α-tocomonoenol (αT1) and none about that of γ-tocomonoenol (γT1). METHODS AND RESULTS: The study investigates the cytotoxicity, uptake, and metabolism of αT1 and γT1 in HepG2 cells compared to the α- and γ-tocopherols (T) and -tocotrienols (T3). None of the studied tocochromanols are cytotoxic up to 100 µmol L-1. The uptake of the γ-congeners is significantly higher than that of the corresponding α-forms, whereas no significant differences are observed based on the degree of saturation of the sidechain. Carboxymethylbutyl-hydroxychromans (CMBHC) are the predominant short-chain metabolites of all tocochromanols and conversion is higher for γT1 than αT1 as well as for the γ-congeners of T and T3. The rate of metabolism increases with the number of double bonds in the sidechain. The rate of metabolic conversion of the T1 is more similar to tocopherols than to that of the tocotrienols. CONCLUSION: This is the first evidence that both αT1 and γT1 follow the same sidechain degradation pathway and exert similar rates of metabolism than tocopherols. Therefore, investigation into the biological activities of tocomonoenols is warranted.


Asunto(s)
Cromanos , Vitamina E , Humanos , Células Hep G2 , Cromanos/farmacología , Vitamina E/farmacología , Vitamina E/análogos & derivados , Vitamina E/metabolismo , Vitamina E/farmacocinética , gamma-Tocoferol/metabolismo , gamma-Tocoferol/farmacología , Tocotrienoles/farmacología , Tocotrienoles/metabolismo , Tocotrienoles/farmacocinética , Supervivencia Celular/efectos de los fármacos , alfa-Tocoferol/farmacología , alfa-Tocoferol/metabolismo , alfa-Tocoferol/análogos & derivados
2.
Int J Mol Sci ; 23(24)2022 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-36555814

RESUMEN

Radiation exposure causes acute damage to hematopoietic and immune cells. To date, there are no radioprotectors available to mitigate hematopoietic injury after radiation exposure. Gamma-tocotrienol (GT3) has demonstrated promising radioprotective efficacy in the mouse and nonhuman primate (NHP) models. We determined GT3-mediated hematopoietic recovery in total-body irradiated (TBI) NHPs. Sixteen rhesus macaques divided into two groups received either vehicle or GT3, 24 h prior to TBI. Four animals in each treatment group were exposed to either 4 or 5.8 Gy TBI. Flow cytometry was used to immunophenotype the bone marrow (BM) lymphoid cell populations, while clonogenic ability of hematopoietic stem cells (HSCs) was assessed by colony forming unit (CFU) assays on day 8 prior to irradiation and days 2, 7, 14, and 30 post-irradiation. Both radiation doses showed significant changes in the frequencies of B and T-cell subsets, including the self-renewable capacity of HSCs. Importantly, GT3 accelerated the recovery in CD34+ cells, increased HSC function as shown by improved recovery of CFU-granulocyte macrophages (CFU-GM) and burst-forming units erythroid (B-FUE), and aided the recovery of circulating neutrophils and platelets. These data elucidate the role of GT3 in hematopoietic recovery, which should be explored as a potential medical countermeasure to mitigate radiation-induced injury to the hematopoietic system.


Asunto(s)
Células Madre Hematopoyéticas , Vitamina E , Ratones , Animales , Macaca mulatta , Vitamina E/farmacología , Cromanos/farmacología , Irradiación Corporal Total
3.
Contrast Media Mol Imaging ; 2022: 7445042, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36072638

RESUMEN

The effect of the TGF-ß pathway-based pituitary tumor of rats on the GH3 cell line after intervention with different concentrations of troglitazone (TGZ) is explored. The CH3 cell line of 24 clean male SD rats with pituitary adenoma is selected. The cells are divided into a blank contrast set and an experimental set. The experimental set is divided into different TGZ concentration sets, including 1 × 10-3 TGZ set, 1 × 10-4 TGZ set, and 1 × 10-5 TGZ set. The cell proliferation is detected by the CCK-8 method, the protein expressions of CD147, TGF-ß1, and MMP-9 are detected by the western blot method, and the relative mRNA expressions of CD147, TGF-ß1, and MMP-9 are detected by the qRT-PCR method. The expression levels of CD147, TGF-ß1, and MMP-9 in CH3 cells of pituitary adenoma rats are notoriously lower, while the expression of CD147, TGF-31, and MMP-9 could be reduced by TGZ acting on the GH3 cell line. The specific mechanism of action of this effect on the invasive ability of GH3 cell lines is multifaceted, suggesting that peroxisome proliferator activator-receptor (PPAR-γ) agonists have good clinical application prospects in tumor therapy and can provide new targets and approaches for tumor drug therapy.


Asunto(s)
Neoplasias Hipofisarias , Tiazolidinedionas , Animales , Línea Celular , Cromanos/farmacología , Masculino , Metaloproteinasa 9 de la Matriz , Neoplasias Hipofisarias/genética , Ratas , Ratas Sprague-Dawley , Tiazolidinedionas/farmacología , Factor de Crecimiento Transformador beta , Factor de Crecimiento Transformador beta1 , Troglitazona
4.
Biol Pharm Bull ; 45(3): 276-283, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35228393

RESUMEN

Lung cancer is the leading cause of cancer-related deaths worldwide. Troglitazone (TGZ), a peroxisome proliferator-activated receptor gamma (PPARγ) ligand, is a potential antitumor agent. However, the action mechanism of TGZ in lung adenocarcinoma cells has not been completely elucidated. To assess this mechanism and the anticancer effects of TGZ in human lung adenocarcinoma cell lines (A549 and H1975), we investigated the involvement of PPARγ, apoptosis, the mitogen-activated protein kinase (MAPK) pathway, protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway, and autophagy. Cell viability was measured using fluorescence-based assays. Apoptotic cells were detected by Hoechst 33342 and Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double staining; protein expression was detected by Western blotting. TGZ inhibited cell proliferation in a dose-dependent manner in both cell lines, and the effect was not suppressed by a PPARγ inhibitor. Additionally, TGZ increased apoptotic cell number and upregulated p38 and c-Jun N-terminal kinase (JNK) phosphorylation; however, p38 and JNK inhibitors did not block TGZ-mediated inhibition of cell proliferation in either cell line. TGZ also upregulated extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation, whereas an ERK1/2 inhibitor enhanced TGZ-mediated cytotoxicity in A549 cells. Additionally, TGZ increased LC3-II expression, and chloroquine (an autophagy inhibitor) attenuated TGZ-mediated inhibition of cell proliferation. These findings suggest that TGZ-induced inhibition of cell proliferation is PPARγ independent. TGZ-mediated inhibition of cell proliferation was accompanied by apoptosis and independent of the MAPK signaling pathway. These results suggest that TGZ inhibits cell proliferation through autophagy-induced cytotoxicity. This study demonstrated that chemotherapy using TGZ may be effective for lung adenocarcinoma.


Asunto(s)
Adenocarcinoma del Pulmón , Tiazolidinedionas , Adenocarcinoma del Pulmón/tratamiento farmacológico , Apoptosis , Autofagia , Línea Celular , Línea Celular Tumoral , Proliferación Celular , Cromanos/farmacología , Humanos , Tiazolidinedionas/farmacología , Troglitazona/farmacología
5.
Bioorg Med Chem ; 57: 116629, 2022 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-35091169

RESUMEN

Malaria is a prevalent and lethal disease. The fast emergence and spread of resistance to current therapies is a major concern and the development of a novel line of therapy that could overcome, the problem of drug resistance, is imperative. Screening of a set of compounds with drug/natural product-based sub-structural motifs led to the identification of spirocyclic chroman-4-one 1 with promising antimalarial activity against the chloroquine-resistant Dd2 and chloroquine-sensitive 3D7 strains of the parasite. Extensive structure-activity and structure-property relationship studies were conducted to identify the essential features necessary for its activity and properties.


Asunto(s)
Antimaláricos/farmacología , Cromanos/farmacología , Malaria/tratamiento farmacológico , Plasmodium/efectos de los fármacos , Compuestos de Espiro/farmacología , Antimaláricos/síntesis química , Antimaláricos/química , Supervivencia Celular/efectos de los fármacos , Cromanos/síntesis química , Cromanos/química , Cristalografía por Rayos X , Relación Dosis-Respuesta a Droga , Células Hep G2 , Humanos , Modelos Moleculares , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Compuestos de Espiro/síntesis química , Compuestos de Espiro/química , Relación Estructura-Actividad
6.
Future Med Chem ; 14(5): 325-342, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34985322

RESUMEN

Aim: Literature reports suggest spirochromanone derivatives exhibit anticancer activity. Methodology: The authors designed and synthesized 18 spirochromanone derivatives (Csp 1-18). The compounds were characterized and evaluated for anticancer activity against human breast cancer (MCF-7) and murine melanoma (B16F10) cell lines. Results: The anticancer activity ranged from 4.34 to 29.31 µm. The most potent compounds, Csp 12 and Csp 18, were less toxic against the human embryonic kidney (HEK-293) cell line and ∼ two/∼fourfold selective toward MCF-7 than B16F10 in comparison to the reference, BG-45. Csp 12 caused 28.6% total apoptosis, leading to significant cytotoxicity, and arrested the G2 phase of the cell cycle in B16F10 cells. A molecular docking study of Csp 12 exhibited effective binding at the active site of the epidermal growth factor receptor kinase domain. Conclusion: This study highlights the importance of spirochromanones as anticancer agents.


Asunto(s)
Antineoplásicos/síntesis química , Cromanos/química , Diseño de Fármacos , Compuestos de Espiro/química , Animales , Antineoplásicos/metabolismo , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Sitios de Unión , Dominio Catalítico , Línea Celular Tumoral , Cromanos/metabolismo , Cromanos/farmacología , Ensayos de Selección de Medicamentos Antitumorales , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/metabolismo , Puntos de Control de la Fase G2 del Ciclo Celular/efectos de los fármacos , Humanos , Ratones , Simulación del Acoplamiento Molecular , Relación Estructura-Actividad
7.
Am J Physiol Renal Physiol ; 322(2): F197-F207, 2022 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-35001664

RESUMEN

KV7 channels, the voltage-gated K+ channels encoded by KCNQ genes, mediate heterogeneous vascular responses in rodents. Postnatal changes in the functional expression of KV7 channels have been reported in rodent saphenous arteries, but their physiological function in the neonatal renal vascular bed is unclear. Here, we report that, unlike adult pigs, only KCNQ1 (KV7.1) out of the five members of KCNQ genes was detected in neonatal pig renal microvessels. KCNQ1 is present in fetal pig kidneys as early as day 50 of gestation, and the level of expression remains the same up to postnatal day 21. Activation of renal vascular smooth muscle cell (SMC) KV7.1 stimulated whole cell currents, inhibited by HMR1556 (HMR), a selective KV7.1 blocker. HMR did not change the steady-state diameter of isolated renal microvessels. Similarly, intrarenal artery infusion of HMR did not alter mean arterial pressure, renal blood flow, and renal vascular resistance in the pigs. An ∼20 mmHg reduction in mean arterial pressure evoked effective autoregulation of renal blood flow, which HMR inhibited. We conclude that 1) the expression of KCNQ isoforms in porcine renal microvessels is dependent on kidney maturation, 2) KV7.1 is functionally expressed in neonatal pig renal vascular SMCs, 3) a decrease in arterial pressure up to 20 mmHg induces renal autoregulation in neonatal pigs, and 4) SMC KV7.1 does not control basal renal vascular tone but contributes to neonatal renal autoregulation triggered by a step decrease in arterial pressure.NEW & NOTEWORTHY KV7.1 is present in fetal pig kidneys as early as day 50 of gestation, and the level of expression remains the same up to postnatal day 21. KV7.1 is functionally expressed in neonatal pig renal vascular smooth muscle cells (SMCs). A decrease in arterial pressure up to 20 mmHg induces renal autoregulation in neonatal pigs. Although SMC KV7.1 does not control basal renal vascular resistance, its inhibition blunts neonatal renal autoregulation engendered by a step decrease in arterial pressure.


Asunto(s)
Presión Arterial/efectos de los fármacos , Cromanos/farmacología , Canal de Potasio KCNQ1/antagonistas & inhibidores , Riñón/irrigación sanguínea , Músculo Liso Vascular/efectos de los fármacos , Miocitos del Músculo Liso/efectos de los fármacos , Bloqueadores de los Canales de Potasio/farmacología , Circulación Renal/efectos de los fármacos , Sulfonamidas/farmacología , Vasodilatación/efectos de los fármacos , Animales , Animales Recién Nacidos , Regulación del Desarrollo de la Expresión Génica , Edad Gestacional , Homeostasis , Canal de Potasio KCNQ1/genética , Canal de Potasio KCNQ1/metabolismo , Microvasos/efectos de los fármacos , Microvasos/metabolismo , Músculo Liso Vascular/metabolismo , Miocitos del Músculo Liso/metabolismo , Transducción de Señal , Sus scrofa
8.
Methods Mol Biol ; 2343: 247-258, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34473328

RESUMEN

A high global prevalence of diabetes and its implications on the heart in vivo and in vitro tools have been pursued to alleviate the complications of high glucose. This chapter oulines the methods used for maintaining H9C2 cardiomyoblasts in vitro and for stimulating hyperglycemic situation. In addition, we present a method to assess cellular GLUT-4 expression using qRT-PCR. This cellular model also allows us to examine the therapeutic approach of an antioxidant, Trolox, for upregulating GLUT-4 and uptake of glucose under hyperglycemic condition.


Asunto(s)
Antioxidantes , Diabetes Mellitus , Miocardio , Reacción en Cadena de la Polimerasa , Antioxidantes/farmacología , Cromanos/farmacología , Glucosa , Transportador de Glucosa de Tipo 4/análisis , Humanos , Miocardio/citología , Reacción en Cadena de la Polimerasa/métodos
9.
Food Funct ; 13(1): 398-410, 2022 Jan 04.
Artículo en Inglés | MEDLINE | ID: mdl-34908071

RESUMEN

γ-Tocotrienol (γ-T3), an isoprenoid phytochemical, has shown the promotion of osteoblast proliferation and differentiation in our previous study. In this study, its underlying mechanism was investigated through regulating the Wnt/ß-catenin signaling pathway in MC3T3-E1 cells. Comparative experiment results showed that γ-T3, not α-tocopherol (α-TOC) increased more significantly the viability and differentiation in MC3T3-E1 cells. After that, the cells were incubated with 10 mM LiCl, or 4 µM γ-T3 with or without 1 µM XAV-939. γ-T3 at 4 µM stimulated the Wnt/ß-catenin signaling pathway by increasing the expression and nuclear accumulation of ß-catenin, and the expressions of their downstream factors, such as cyclin-D1, c-Myc, BMP2 and BMP-4 in MC3T3-E1 cells. γ-T3 not only upregulated the viability, induced G0/G1 to the S phase, and promoted the expressions of PCNA (Proliferating Cell Nuclear Antigen) and Ki-67, but also increased ALP activity and the expressions of ON, OPN and OCN. Moreover, the effects of γ-T3 on the MC3T3-E1 cells resembled the actions of LiCl, an activator of the Wnt/ß-catenin signaling pathway. Notably, all these effects of γ-T3 on the MC3T3-E1 cells were completely blocked by the Wnt/ß-catenin signaling pathway inhibitor XAV-939. Our data demonstrated that γ-T3 can target ß-catenin to enhance the Wnt/ß-catenin signaling pathway, which led to increased expressions of the downstream cell proliferation and cell cycle-associated (cyclin D1 and c-myc), and cell differentiation-associated (BMP-2 and BMP-4) target genes, and ultimately promoted MC3T3-E1 cell proliferation and differentiation. Therefore, γ-T3 may be a potential agent to prevent and reverse osteoporosis due to its safety and powerful abilities of osteogenesis.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Cromanos/farmacología , Vitamina E/análogos & derivados , Vía de Señalización Wnt/efectos de los fármacos , Animales , Línea Celular , Proliferación Celular/efectos de los fármacos , Ratones , Osteoblastos/efectos de los fármacos , Vitamina E/farmacología
10.
Int J Mol Sci ; 22(23)2021 Nov 24.
Artículo en Inglés | MEDLINE | ID: mdl-34884479

RESUMEN

Ischemia-induced mitochondrial dysfunction and ATP depletion in the kidney result in disruption of primary functions and acute injury of the kidney. This study tested whether γ-tocotrienol (GTT), a member of the vitamin E family, protects mitochondrial function, reduces ATP deficits, and improves renal functions and survival after ischemia/reperfusion injury. Vehicle or GTT (200 mg/kg) were administered to mice 12 h before bilateral kidney ischemia, and endpoints were assessed at different timepoints of reperfusion. GTT treatment reduced decreases in state 3 respiration and accelerated recovery of this function after ischemia. GTT prevented decreases in activities of complexes I and III of the respiratory chain, and blocked ischemia-induced decreases in F0F1-ATPase activity and ATP content in renal cortical tissue. GTT improved renal morphology at 72 h after ischemia, reduced numbers of necrotic proximal tubular and inflammatory cells, and enhanced tubular regeneration. GTT treatment ameliorated increases in plasma creatinine levels and accelerated recovery of creatinine levels after ischemia. Lastly, 89% of mice receiving GTT and 70% of those receiving vehicle survived ischemia. Conclusions: Our data show novel observations that GTT administration improves mitochondrial respiration, prevents ATP deficits, promotes tubular regeneration, ameliorates decreases in renal functions, and increases survival after acute kidney injury in mice.


Asunto(s)
Lesión Renal Aguda/tratamiento farmacológico , Cromanos/farmacología , Transporte de Electrón/efectos de los fármacos , Metabolismo Energético , Mitocondrias/efectos de los fármacos , Sustancias Protectoras/farmacología , Daño por Reperfusión/tratamiento farmacológico , Vitamina E/análogos & derivados , Lesión Renal Aguda/etiología , Lesión Renal Aguda/metabolismo , Lesión Renal Aguda/patología , Adenosina Trifosfato/metabolismo , Animales , Masculino , Ratones , Ratones Endogámicos C57BL , Mitocondrias/patología , Daño por Reperfusión/etiología , Daño por Reperfusión/metabolismo , Daño por Reperfusión/patología , Vitamina E/farmacología
11.
Molecules ; 26(21)2021 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-34771113

RESUMEN

Phytochemical investigation of the ethanol extract of underground parts of Iris tenuifolia Pall. afforded five new compounds; an unusual macrolide termed moniristenulide (1), 5-methoxy-6,7-methylenedioxy-4-O-2'-cycloflavan (2), 5,7,2',3'-tetrahydroxyflavanone (3), 5-hydroxy-6,7-dimethoxyisoflavone-2'-O-ß-d-glucopyranoside (9), 5,2',3'-dihydroxy-6,7-dimethoxyisoflavone (10), along with seven known compounds (4-8, 11-12). The structures of all purified compounds were established by analysis of 1D and 2D NMR spectroscopy and HR-ESI-MS. The antimicrobial activity of the compounds 1-3, 5, 9, and 10 was investigated using the agar diffusion method against fungi, Gram-positive and Gram-negative bacteria. In consequence, new compound 3 was found to possess the highest antibacterial activity against Enterococcus faecalis VRE and Mycobacterium vaccae. Cell proliferation and cytotoxicity tests were also applied on all isolated compounds and plant crude extract in vitro with the result of potent inhibitory effect against leukemia cells. In particular, the newly discovered isoflavone 10 was active against both of the leukemia cells K-562 and THP-1 while 4-6 of the flavanone type compounds were active against only THP-1.


Asunto(s)
Antiinfecciosos/farmacología , Antineoplásicos/farmacología , Cromanos/farmacología , Género Iris/química , Extractos Vegetales/farmacología , Antiinfecciosos/química , Antineoplásicos/química , Línea Celular , Supervivencia Celular/efectos de los fármacos , Cromanos/química , Relación Dosis-Respuesta a Droga , Humanos , Espectroscopía de Resonancia Magnética , Conformación Molecular , Estructura Molecular , Extractos Vegetales/química
12.
J Nat Prod ; 84(11): 2953-2960, 2021 11 26.
Artículo en Inglés | MEDLINE | ID: mdl-34787427

RESUMEN

Penicisteckins A-D (1-4), two pairs of atropodiastereomeric biaryl-type hetero- and homodimeric bis-isochromans with 7,5'- and 7,7'-linkages and a pair of atropodiastereomeric 2-(isochroman-5-yl)-1,4-benzoquinone derivatives [penicisteckins E (5) and F (6)], were isolated from the Penicillium steckii HNNU-5B18. Their structures including the absolute configuration were determined by extensive spectroscopic and single-crystal X-ray diffraction analysis and TDDFT-ECD calculations. Both the bis-isochromans and the isochroman/1,4-benzoquinone conjugates represent novel biaryl scaffolds containing both central and axial chirality elements. The monomer anserinone B (8) exhibited potent antibacterial activities against Staphylococcus aureus ATCC 29213 and methicillin-resistant Staphylococcus aureus with minimal inhibition concentration values ranging from 2 to 8 µg mL-1. Plausible biosynthetic pathways of 1-6 are proposed, which suggest how the absolute configurations of the isolates were established during the biosynthetic scheme.


Asunto(s)
Antibacterianos/aislamiento & purificación , Cromanos/aislamiento & purificación , Penicillium/metabolismo , Antibacterianos/química , Antibacterianos/farmacología , Vías Biosintéticas , Cromanos/química , Cromanos/farmacología , Staphylococcus aureus/efectos de los fármacos
13.
Int J Mol Sci ; 22(17)2021 Aug 31.
Artículo en Inglés | MEDLINE | ID: mdl-34502402

RESUMEN

Microglial functioning depends on Ca2+ signaling. By using Ca2+ sensitive fluorescence dye, we studied how inhibition of mitochondrial respiration changed spontaneous Ca2+ signals in soma of microglial cells from 5-7-day-old rats grown under normoxic and mild-hypoxic conditions. In microglia under normoxic conditions, metformin or rotenone elevated the rate and the amplitude of Ca2+ signals 10-15 min after drug application. Addition of cyclosporin A, a blocker of mitochondrial permeability transition pore (mPTP), antioxidant trolox, or inositol 1,4,5-trisphosphate receptor (IP3R) blocker caffeine in the presence of rotenone reduced the elevated rate and the amplitude of the signals implying sensitivity to reactive oxygen species (ROS), and involvement of mitochondrial mPTP together with IP3R. Microglial cells exposed to mild hypoxic conditions for 24 h showed elevated rate and increased amplitude of Ca2+ signals. Application of metformin or rotenone but not phenformin before mild hypoxia reduced this elevated rate. Thus, metformin and rotenone had the opposing fast action in normoxia after 10-15 min and the slow action during 24 h mild-hypoxia implying activation of different signaling pathways. The slow action of metformin through inhibition of complex I could stabilize Ca2+ homeostasis after mild hypoxia and could be important for reduction of ischemia-induced microglial activation.


Asunto(s)
Señalización del Calcio/efectos de los fármacos , Metformina/farmacología , Animales , Cafeína/farmacología , Señalización del Calcio/fisiología , Cromanos/farmacología , Ciclosporina/farmacología , Complejo I de Transporte de Electrón/metabolismo , Femenino , Hipoxia/genética , Hipoxia/metabolismo , Masculino , Metformina/metabolismo , Microglía/efectos de los fármacos , Microglía/metabolismo , Mitocondrias/metabolismo , Proteínas de Transporte de Membrana Mitocondrial/metabolismo , Neuronas/metabolismo , Cultivo Primario de Células , Ratas , Especies Reactivas de Oxígeno/metabolismo , Rotenona/farmacología
14.
Naunyn Schmiedebergs Arch Pharmacol ; 394(11): 2289-2307, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34468817

RESUMEN

At present, thiamine deficiency (TD) is managed with administration of high doses of thiamine. Even so, severe and permanent neurological disorders can occur in recurrent episodes of TD. In this study, we used a murine model to assess the efficacy of TD recovery treatments using thiamine with or without additional administration of the antioxidant Trolox or the anti-inflammatory dimethyl sulfoxide (DMSO) after a single or recurrent episode of TD. TD was induced for 9 days with deficient chow and pyrithiamine, and the recovery period was 7 days with standard amounts of chow and thiamine, Trolox, and/or DMSO. After these periods, we evaluated behavior, histopathology, and ERK1/2 modulation in the brain. Deficient animals showed reductions in locomotor activity, motor coordination, and spatial memory. Morphologically, after a single episode of TD and recovery, deficient mice showed neuronal vacuolization in the dorsal thalamus and, after two episodes, a reduction in neuronal cell number. These effects were attenuated or reversed by the recovery treatments, mainly in the treatments with thiamine associated with Trolox or DMSO. Deficient animals showed a strong increase in ERK1/2 phosphorylation in the thalamus, hippocampus, and cerebral cortex after one deficiency episode and recovery. Interestingly, after recurrent TD and recovery, ERK1/2 phosphorylation remained high only in the deficient mice treated with thiamine and/or Trolox or thiamine with DMSO. Our data suggest that a protocol for TD treatment with thiamine in conjunction with Trolox or DMSO enhances the recovery of animals and possibly minimizes the late neurological sequelae.


Asunto(s)
Cromanos/farmacología , Dimetilsulfóxido/farmacología , Deficiencia de Tiamina/tratamiento farmacológico , Tiamina/administración & dosificación , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacología , Antioxidantes/administración & dosificación , Antioxidantes/farmacología , Conducta Animal/efectos de los fármacos , Cromanos/administración & dosificación , Dimetilsulfóxido/administración & dosificación , Modelos Animales de Enfermedad , Locomoción/efectos de los fármacos , Masculino , Ratones , Recurrencia , Memoria Espacial/efectos de los fármacos
15.
Molecules ; 26(15)2021 Jul 21.
Artículo en Inglés | MEDLINE | ID: mdl-34361545

RESUMEN

In this study, using the botanical active component thiochromanone as the lead compound, a total of 32 new thiochromanone derivatives containing a carboxamide moiety were designed and synthesized and their in vitro antibacterial activities against Xanthomonas oryzae pv. oryzae (Xoo), Xanthomonas oryzae pv. oryzicolaby (Xoc), and Xanthomonas axonopodis pv. citri (Xac) were determined, as well as their in vitro antifungal activities against Botryosphaeria dothidea (B. dothidea), Phomopsis sp., and Botrytis cinerea (B. cinerea). Bioassay results demonstrated that some of the target compounds exhibited moderate to good in vitro antibacterial and antifungal activities. In particular, compound 4e revealed excellent in vitro antibacterial activity against Xoo, Xoc, and Xac, and its EC50 values of 15, 19, and 23 µg/mL, respectively, were superior to those of Bismerthiazol and Thiodiazole copper. Meanwhile, compound 3b revealed moderate in vitro antifungal activity against B. dothidea at 50 µg/mL, and the inhibition rate reached 88%, which was even better than that of Pyrimethanil, however, lower than that of Carbendazim. To the best of our knowledge, this is the first report on the antibacterial and antifungal activities of this series of novel thiochromanone derivatives containing a carboxamide moiety.


Asunto(s)
Botrytis/crecimiento & desarrollo , Cromanos , Phomopsis/crecimiento & desarrollo , Xanthomonas axonopodis/crecimiento & desarrollo , Xanthomonas/crecimiento & desarrollo , Antifúngicos/síntesis química , Antifúngicos/química , Antifúngicos/farmacología , Cromanos/síntesis química , Cromanos/química , Cromanos/farmacología , Relación Estructura-Actividad
16.
Molecules ; 26(16)2021 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-34443516

RESUMEN

Oxidative stress and inflammation are two conditions that coexist in many multifactorial diseases such as atherosclerosis and neurodegeneration. Thus, the design of multifunctional compounds that can concurrently tackle two or more therapeutic targets is an appealing approach. In this study, the basic NSAID structure was fused with the antioxidant moieties 3,5-di-tert-butyl-4-hydroxybenzoic acid (BHB), its reduced alcohol 3,5-di-tert-butyl- 4-hydroxybenzyl alcohol (BHBA), or 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox), a hydrophilic analogue of α-tocopherol. Machine learning algorithms were utilized to validate the potential dual effect (anti-inflammatory and antioxidant) of the designed analogues. Derivatives 1-17 were synthesized by known esterification methods, with good to excellent yields, and were pharmacologically evaluated both in vitro and in vivo for their antioxidant and anti-inflammatory activity, whereas selected compounds were also tested in an in vivo hyperlipidemia protocol. Furthermore, the activity/binding affinity of the new compounds for lipoxygenase-3 (LOX-3) was studied not only in vitro but also via molecular docking simulations. Experimental results demonstrated that the antioxidant and anti-inflammatory activities of the new fused molecules were increased compared to the parent molecules, while molecular docking simulations validated the improved activity and revealed the binding mode of the most potent inhibitors. The purpose of their design was justified by providing a potentially safer and more efficient therapeutic approach for multifactorial diseases.


Asunto(s)
Antioxidantes/química , Aterosclerosis/tratamiento farmacológico , Hiperlipidemias/tratamiento farmacológico , Inflamación/tratamiento farmacológico , Inhibidores de la Lipooxigenasa/química , Antiinflamatorios/síntesis química , Antiinflamatorios/química , Antiinflamatorios/farmacología , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/química , Antioxidantes/síntesis química , Antioxidantes/farmacología , Aterosclerosis/patología , Cromanos/química , Cromanos/farmacología , Diseño de Fármacos , Humanos , Hiperlipidemias/patología , Hipolipemiantes/síntesis química , Hipolipemiantes/química , Hipolipemiantes/farmacología , Inflamación/patología , Lipooxigenasa/química , Lipooxigenasa/efectos de los fármacos , Inhibidores de la Lipooxigenasa/síntesis química , Inhibidores de la Lipooxigenasa/farmacología , Simulación del Acoplamiento Molecular , Degeneración Nerviosa/tratamiento farmacológico , Degeneración Nerviosa/patología , Estrés Oxidativo/efectos de los fármacos , Parabenos/química , Parabenos/farmacología , Relación Estructura-Actividad
17.
Stem Cell Reports ; 16(9): 2197-2212, 2021 09 14.
Artículo en Inglés | MEDLINE | ID: mdl-34329596

RESUMEN

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is often caused by an adenine to guanine variant at m.3243 (m.3243A>G) of the MT-TL1 gene. To understand how this pathogenic variant affects the nervous system, we differentiated human induced pluripotent stem cells (iPSCs) into excitatory neurons with normal (low heteroplasmy) and impaired (high heteroplasmy) mitochondrial function from MELAS patients with the m.3243A>G pathogenic variant. We combined micro-electrode array (MEA) measurements with RNA sequencing (MEA-seq) and found reduced expression of genes involved in mitochondrial respiration and presynaptic function, as well as non-cell autonomous processes in co-cultured astrocytes. Finally, we show that the clinical phase II drug sonlicromanol can improve neuronal network activity when treatment is initiated early in development. This was intricately linked with changes in the neuronal transcriptome. Overall, we provide insight in transcriptomic changes in iPSC-derived neurons with high m.3243A>G heteroplasmy, and show the pathology is partially reversible by sonlicromanol.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/genética , Cromanos/farmacología , Heteroplasmia/genética , Células Madre Pluripotentes Inducidas/metabolismo , Neuronas/metabolismo , ARN de Transferencia de Leucina/genética , Transcriptoma , Animales , Astrocitos/metabolismo , Técnicas de Cultivo de Célula , Células Cultivadas , ADN Mitocondrial/genética , ADN Mitocondrial/metabolismo , Modelos Animales de Enfermedad , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/efectos de los fármacos , Predisposición Genética a la Enfermedad , Humanos , Células Madre Pluripotentes Inducidas/citología , Encefalomiopatías Mitocondriales/diagnóstico , Encefalomiopatías Mitocondriales/etiología , Encefalomiopatías Mitocondriales/metabolismo , Neuronas/citología , Fenotipo , Ratas
18.
J Med Chem ; 64(13): 9302-9320, 2021 07 08.
Artículo en Inglés | MEDLINE | ID: mdl-34152756

RESUMEN

A series of multitarget-directed ligands (MTDLs) was designed by functionalizing a pseudo-irreversible butyrylcholinesterase (BChE) inhibitor. The obtained hybrids were investigated in vitro regarding their hBChE and hAChE inhibition, their enzyme kinetics, and their antioxidant physicochemical properties (DPPH, ORAC, metal chelating). In addition, in vitro assays were applied to investigate antioxidant effects using murine hippocampal HT22 cells and immunomodulatory effects on the murine microglial N9 cell line. The MTDLs retained their antioxidative properties compared to the parent antioxidant-moieties in vitro and the inhibition of hBChE was maintained in the submicromolar range. Representative compounds were tested in a pharmacological Alzheimer's disease (AD) mouse model and demonstrated very high efficacy at doses as low as 0.1 mg/kg. The most promising compound was also tested in BChE-/- mice and showed reduced efficacy. In vivo neuroprotection by BChE inhibition can be effectively enhanced by incorporation of structurally diverse antioxidant moieties.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Antioxidantes/farmacología , Inhibidores de la Colinesterasa/farmacología , Modelos Animales de Enfermedad , Fármacos Neuroprotectores/farmacología , Acetilcolinesterasa/metabolismo , Enfermedad de Alzheimer/metabolismo , Animales , Antioxidantes/síntesis química , Antioxidantes/química , Compuestos de Bifenilo/antagonistas & inhibidores , Butirilcolinesterasa/deficiencia , Butirilcolinesterasa/metabolismo , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Inhibidores de la Colinesterasa/síntesis química , Inhibidores de la Colinesterasa/química , Cromanos/síntesis química , Cromanos/química , Cromanos/farmacología , Cinamatos/síntesis química , Cinamatos/química , Cinamatos/farmacología , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Melatonina/síntesis química , Melatonina/química , Melatonina/farmacología , Ratones , Estructura Molecular , Fármacos Neuroprotectores/síntesis química , Fármacos Neuroprotectores/química , Picratos/antagonistas & inhibidores , Relación Estructura-Actividad
19.
Molecules ; 26(10)2021 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-34069070

RESUMEN

A series of novel thiochromanone derivatives containing a sulfonyl hydrazone moiety were designed and synthesized. Their structures were determined by 1H-NMR, 13C-NMR, and HRMS. Bioassay results showed that most of the target compounds revealed moderate to good antibacterial activities against Xanthomonas oryzae pv. oryzae, Xanthomonas oryzae pv. oryzicolaby, and Xanthomonas axonopodis pv. citri. Compound 4i had the best inhibitory activity against Xanthomonas oryzae pv. oryzae, Xanthomonas oryzae pv. oryzicolaby, and Xanthomonas axonopodis pv. citri, with the EC50 values of 8.67, 12.65, and 10.62 µg/mL, which were superior to those of Bismerthiazol and Thiodiazole-copper. Meanwhile, bioassay results showed that all of the target compounds proved to have lower antifungal activities against Sclerotinia sclerotiorum, Fusarium oxysporum, Gibberella zeae, Rhizoctonia solani, Verticillium dahlia, and Botrytis cinerea than those of Carbendazim.


Asunto(s)
Cromanos/síntesis química , Cromanos/farmacología , Hidrazonas/síntesis química , Hidrazonas/farmacología , Sulfonas/síntesis química , Sulfonas/farmacología , Antibacterianos/farmacología , Antifúngicos/farmacología , Cromanos/química , Hongos/efectos de los fármacos , Hidrazonas/química , Pruebas de Sensibilidad Microbiana , Relación Estructura-Actividad , Xanthomonas/efectos de los fármacos
20.
Molecules ; 26(11)2021 May 25.
Artículo en Inglés | MEDLINE | ID: mdl-34070610

RESUMEN

As a significant co-activator involved in cell cycle and cell growth, differentiation and development, p300/CBP has shown extraordinary potential target in cancer therapy. Herein we designed new compounds from the lead compound A-485 based on molecular dynamic simulations. A series of new spirocyclic chroman derivatives was prepared, characterized and proven to be a potential treatment of prostate cancer. The most potent compound B16 inhibited the proliferation of enzalutamide-resistant 22Rv1 cells with an IC50 value of 96 nM. Furthermore, compounds B16-P2 displayed favorable overall pharmacokinetic profiles, and better tumor growth inhibition than A-485 in an in vivo xenograft model.


Asunto(s)
Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Cromanos/química , Neoplasias de la Próstata/tratamiento farmacológico , Proliferación Celular/efectos de los fármacos , Cromanos/farmacología , Xenoinjertos , Humanos , Concentración 50 Inhibidora , Masculino , Simulación del Acoplamiento Molecular , Neoplasias de la Próstata/patología , Análisis Espectral/métodos , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...